• Muna Therapeutics reported positive Phase 1 results for oral TREM2 modulator MNA-001, supporting development in early Alzheimer's disease.
• No deaths, serious adverse events or adverse-event-related discontinuations occurred; most adverse events were mild.
• Central nervous system exposure reached a cerebrospinal fluid-to-plasma ratio of approximately 1.7; target engagement was dose-dependent.
• Repeated dosing shifted elderly volunteers' age-related brain inflammation markers toward levels seen in younger healthy participants.
• Phase 2 is expected to start in Q2 2027, testing two doses against placebo over 48 weeks, with plasma pTau217 change primary.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. V-Bio Ventures published the original content used to generate this news brief on October 22, 2026, and is solely responsible for the information contained therein.